Medication info

Ranasid Injection (Ranitidine Hydrochloride)

Prescription medicationApproval withdrawn
Ingredient · strength
Ranitidine Hydrochloride›Strength being verified
Manufacturer / importer
Kujoo Pharmaceutical Co., Ltd.
Appearance
A clear colorless to pale yellow liquid filled in a brown ampoule.
Packaging
2mL*1 ampoule, 50 ampoules
Approval status
Approval withdrawn

MFDS item code 199602550 · Notified 1996.09.20

This product's status changed to Approval withdrawn on 2023.06.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of acid-related disorders (e.g., ulcers) and upper gastrointestinal bleeding, and prevention of Mendelson syndrome
Who uses it
Adults · Children
Adult dosage
Adults: Administer 50mg of ranitidine per dose by intravenous or intramuscular injection 3~4 times daily. For intravenous injection, dilute 50mg of this medicine in 20ml of normal saline injection or glucose injection and inject slowly over at least 2 minutes, or mix it with an infusion solution and administer by intravenous drip over 2 hours at a rate of 25mg/hr. For upper gastrointestinal bleeding, the effect generally appears within 1 week. Once oral administration is possible, switch to oral administration. For preanesthetic medication (prevention of Mendelson syndrome), inject 50mg intramuscularly or slowly intravenously over 1 minute, 45~60 minutes before induction of anesthesia. Patients with renal impairment: For patients with severe renal impairment whose creatinine clearance is 50㎖/min or less, reduce the dose to 25mg per administration or extend the dosing interval and administer 50mg every 18~24 hours. Depending on the patient's condition, 50mg may be administered every 12 hours. Hemodialysis reduces the drug concentration in the blood, so readjust the dosing schedule immediately after hemodialysis. Adjust the dose as appropriate according to age and symptoms.
Children's dosage
Clinical studies in children have not been established.

Ingredients

Manufacturer
Kujoo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (e.g., ulcers) and upper gastrointestinal bleeding, and prevention of Mendelson syndrome

  • Gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
  • gastroesophageal reflux disease
  • Mendelson's syndrome
  • post-surgical ulcers
  • upper gastrointestinal bleeding
  • peptic ulcer
  • acute stress ulcer
  • acute gastric mucosal lesions.
View approved original text

This medication is used to treat gastric and duodenal ulcers, and conditions such as Zollinger-Ellison syndrome related to excessive gastric acid secretion. It is also helpful in treating gastroesophageal reflux disease and is administered to prevent Mendelson's syndrome before anesthesia. It is effective in treating ulcers that may occur post-surgery, acute stress ulcers of the stomach, and upper gastrointestinal bleeding. Overall, this medication is broadly used for the treatment and prevention of various gastrointestinal conditions.

Dosage and Administration

Adult dosage

Adults: Administer 50mg of ranitidine per dose by intravenous or intramuscular injection 3~4 times daily. For intravenous injection, dilute 50mg of this medicine in 20ml of normal saline injection or glucose injection and inject slowly over at least 2 minutes, or mix it with an infusion solution and administer by intravenous drip over 2 hours at a rate of 25mg/hr. For upper gastrointestinal bleeding, the effect generally appears within 1 week. Once oral administration is possible, switch to oral administration. For preanesthetic medication (prevention of Mendelson syndrome), inject 50mg intramuscularly or slowly intravenously over 1 minute, 45~60 minutes before induction of anesthesia. Patients with renal impairment: For patients with severe renal impairment whose creatinine clearance is 50㎖/min or less, reduce the dose to 25mg per administration or extend the dosing interval and administer 50mg every 18~24 hours. Depending on the patient's condition, 50mg may be administered every 12 hours. Hemodialysis reduces the drug concentration in the blood, so readjust the dosing schedule immediately after hemodialysis. Adjust the dose as appropriate according to age and symptoms.

Children's dosage

Clinical studies in children have not been established.

Precautions

This medication must be handled with care when cutting the ampoule to avoid glass fragments entering, especially when used on children or the elderly. This medication should not be used in patients with hypersensitivity to its components. Patients with impaired kidney function may experience increased blood concentration as this medication is excreted through the kidneys, necessitating adjustments to dosage or dosing intervals. Caution should be exercised in patients with compromised liver function, hypersensitivity to medications, and elderly patients. Patients with a history of acute porphyria should avoid this medication as it may provoke seizures. This medication may rarely cause severe allergic reactions such as anaphylactic shock; if any unusual symptoms appear during administration, it should be discontinued immediately, and appropriate treatment should be received. Allergic reactions such as urticaria, rash, bronchospasm, and hypotension may occur; if such symptoms appear, use should be discontinued. Various side effects such as blood abnormalities, liver dysfunction, heart rhythm abnormalities, gastrointestinal symptoms, and neurological abnormalities have been reported rarely; immediate consultation with healthcare providers is advised if symptoms occur. The risk of pneumonia may increase in elderly patients or those with chronic illnesses, requiring careful monitoring. This medication may interact with other drugs, so it is crucial to inform healthcare providers of any currently taken medications. Women who are pregnant or breastfeeding should use this medication cautiously as it may affect the fetus or child. Safety in pediatric patients has not been sufficiently established; caution is advised during use. In the event of overdose, symptomatic treatment like vomiting or gastric lavage may be necessary, and if needed, removal via dialysis can be performed. Intramuscular injection may cause pain or hardening at the injection site, which should be noted with caution. For patients concerned about heart rhythm abnormalities, the infusion rate should be controlled slowly. This medication may mask symptoms of gastric cancer, so gastric ulcer patients or those over mid-age with newly appearing dyspeptic symptoms should have malignancy screened prior to treatment. Prolonged use may affect eye health; therefore, careful use with regular ophthalmological examinations is recommended.

Side effects

  • Anaphylactic shock
  • urticaria
  • angioedema
  • rash
  • fever
  • bronchospasm
  • hypotension
  • chest pain
  • vascular edema
  • granulocytopenia
Show 58 more
  • elevated serum creatinine levels
  • leukopenia
  • thrombocytopenia
  • bone marrow suppression
  • aplastic anemia
  • refractory anemia
  • agranulocytosis
  • pancytopenia
  • acquired immune hemolytic anemia
  • eosinophilia
  • liver dysfunction
  • jaundice
  • hepatitis
  • bradycardia
  • heart block
  • tachycardia
  • vasculitis
  • cardiac arrest
  • constipation
  • nausea
  • vomiting
  • abdominal distension
  • abdominal pain
  • loss of appetite
  • diarrhea
  • acute pancreatitis
  • dizziness
  • drowsiness
  • convulsions
  • headache
  • heaviness in the head
  • insomnia
  • agitation
  • anxiety
  • mental confusion
  • depression
  • hallucinations
  • blurred vision
  • involuntary movement disorder
  • consciousness disorder
  • myotonic contraction
  • gynecomastia
  • hypergalactorrhea
  • erectile dysfunction
  • decreased libido
  • arthralgia
  • myalgia
  • rhabdomyolysis
  • skin rash
  • erythema multiforme
  • alopecia
  • glossitis
  • pruritus
  • Stevens-Johnson syndrome
  • Riel syndrome
  • acute interstitial nephritis
  • pain at the injection site
  • induration at the injection site

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container that blocks light, kept at a temperature between 1 to 30 degrees Celsius. Proper storage helps maintain efficacy and prevents degradation.

Appearance and packaging

Appearance

A clear colorless to pale yellow liquid filled in a brown ampoule.

Package unit

2mL*1 ampoule, 50 ampoules

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.